Middle East Healthcare Company

SASE:4009 Stock Report

Market Cap: ر.س5.3b

Middle East Healthcare Valuation

Is 4009 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4009 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
ر.س120.96
Fair Value
52.4% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: 4009 (SAR57.55) is trading below our estimate of fair value (SAR120.96)

Significantly Below Fair Value: 4009 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4009?

Key metric: As 4009 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4009. This is calculated by dividing 4009's market cap by their current earnings.
What is 4009's PE Ratio?
PE Ratio13.3x
Earningsر.س398.14m
Market Capر.س5.31b

Price to Earnings Ratio vs Peers

How does 4009's PE Ratio compare to its peers?

The above table shows the PE ratio for 4009 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.9x
4007 Al Hammadi Holding
17x7.76%ر.س5.9b
4005 National Medical Care
24.8x11.63%ر.س7.5b
4019 Specialized Medical
32.7xn/aر.س5.4b
4018 Almoosa Health
57.2x25.65%ر.س7.6b
4009 Middle East Healthcare
13.3x7.49%ر.س5.3b

Price-To-Earnings vs Peers: 4009 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (32.9x).

Price to Earnings Ratio vs Industry

How does 4009's PE Ratio compare vs other companies in the SA Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4009 13.3xIndustry Avg. 25.1xNo. of Companies3PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4009 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the SA Healthcare industry average (27.2x).

Price to Earnings Ratio vs Fair Ratio

What is 4009's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4009 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.3x
Fair PE Ratio20.1x

Price-To-Earnings vs Fair Ratio: 4009 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the estimated Fair Price-To-Earnings Ratio (20.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4009 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س57.55
ر.س81.71
+41.99%
7.26%ر.س92.30ر.س75.00n/a8
Jul ’26ر.س55.75
ر.س81.71
+46.57%
7.26%ر.س92.30ر.س75.00n/a8
Jun ’26ر.س58.70
ر.س83.58
+42.39%
6.83%ر.س92.30ر.س76.00n/a6
May ’26ر.س69.00
ر.س83.58
+21.14%
6.83%ر.س92.30ر.س76.00n/a6
Apr ’26ر.س68.50
ر.س84.79
+23.77%
7.13%ر.س92.30ر.س76.00n/a7
Mar ’26ر.س76.90
ر.س91.30
+18.73%
6.10%ر.س102.00ر.س82.00n/a7
Feb ’26ر.س81.70
ر.س88.83
+8.73%
8.92%ر.س102.00ر.س75.00n/a7
Jan ’26ر.س68.50
ر.س88.83
+29.68%
8.92%ر.س102.00ر.س75.00n/a7
Dec ’25ر.س69.60
ر.س88.11
+26.60%
9.09%ر.س102.00ر.س75.00n/a7
Nov ’25ر.س72.30
ر.س88.11
+21.87%
9.09%ر.س102.00ر.س75.00n/a7
Oct ’25ر.س72.00
ر.س88.11
+22.38%
9.09%ر.س102.00ر.س75.00n/a7
Sep ’25ر.س75.70
ر.س88.11
+16.40%
9.09%ر.س102.00ر.س75.00n/a7
Aug ’25ر.س77.40
ر.س94.97
+22.70%
4.66%ر.س102.00ر.س88.00n/a7
Jul ’25ر.س85.80
ر.س94.97
+10.69%
4.66%ر.س102.00ر.س88.00ر.س55.757
Jun ’25ر.س73.20
ر.س92.74
+26.70%
4.58%ر.س100.00ر.س86.40ر.س58.707
May ’25ر.س90.00
ر.س84.20
-6.44%
23.53%ر.س107.00ر.س42.00ر.س69.007
Apr ’25ر.س89.10
ر.س86.06
-3.42%
25.44%ر.س113.00ر.س42.00ر.س68.507
Mar ’25ر.س121.60
ر.س86.06
-29.23%
25.44%ر.س113.00ر.س42.00ر.س76.907
Feb ’25ر.س108.20
ر.س80.06
-26.01%
24.09%ر.س107.00ر.س42.00ر.س81.707
Jan ’25ر.س90.40
ر.س74.20
-17.92%
22.43%ر.س92.00ر.س40.00ر.س68.507
Dec ’24ر.س78.40
ر.س68.73
-12.34%
22.80%ر.س92.00ر.س40.00ر.س69.607
Nov ’24ر.س69.40
ر.س64.16
-7.55%
25.09%ر.س92.00ر.س35.00ر.س72.307
Oct ’24ر.س59.70
ر.س63.01
+5.55%
25.32%ر.س92.00ر.س35.00ر.س72.007
Sep ’24ر.س58.70
ر.س62.73
+6.86%
26.25%ر.س92.00ر.س33.00ر.س75.707
Aug ’24ر.س63.20
ر.س62.68
-0.82%
28.37%ر.س92.00ر.س33.00ر.س77.406
Jul ’24n/a
ر.س62.68
0%
28.37%ر.س92.00ر.س33.00ر.س85.806
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
ر.س81.71
Fair Value
29.6% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/15 07:19
End of Day Share Price 2025/07/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Middle East Healthcare Company is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ibrahim ElaiwatAljazira Capital Company
Jassim Al-JubranAljazira Capital Company
Madhu AppissaAl Rajhi Capital